Lakewood, CO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC: KRTL) is strategically expanding its presence in the heart of South America, where biodiversity flourishes and untapped resources promise new frontiers in medicine. Recognizing Bolivia’s vast potential, KRTL’s subsidiaries, KRTL Biotech, Inc. and KRTL International Corp., have formed a strategic joint venture with Centro de Investigaciones Químicas - CIQ S.R.L., a leading Bolivian research and manufacturing institution led by the esteemed Dr. Bascope.
A Vision for Sustainable Growth
For decades, the global pharmaceutical supply chain has been dominated by traditional hubs like China and India. However, shifting economic landscapes and growing concerns over sustainability have created an opportunity for diversification. Bolivia, with its rich natural resources and cost-effective production, stands as an emerging leader in the biotech and pharmaceutical sectors.
KRTL’s joint venture with CIQ goes beyond securing a 19.98% stake (9.99% each for KRTL Biotech and KRTL International) in 3451.5 acres of land, equating to 689.9 acres. This land, located in a strategic area of the Amazon region, is being solicited and finalized by CIQ with the Bolivian government. The partnership establishes a foundation for sustainable API extraction, advanced research, and manufacturing, enhancing intrinsic value while reducing costs for its partners. By leveraging Bolivia’s unique plant-based and mineral resources, KRTL Biotech is positioning itself at the forefront of next-generation pharmaceutical innovation.
Bridging Markets: Bolivia to the U.S.
Through this joint venture, KRTL Biotech will introduce CIQ’s real estate holdings, cosmetic products, raw materials, minerals, and active pharmaceutical ingredients (APIs) into the U.S. market through a structured regulatory pathway. By aligning with FDA registration requirements and international pharmaceutical regulations, this partnership ensures seamless distribution and market entry while maintaining strict regulatory compliance. This collaboration paves the way for broader market accessibility and sustainable commercialization of CIQ’s natural-based innovations.
The Role of CIQ in This Strategic Expansion
CIQ is no ordinary research institution. As a hub of pharmaceutical and cosmetic innovation, it specializes in the extraction of high-value botanical ingredients sourced from Bolivia’s diverse ecosystems, including the Amazon rainforest and the Andes Mountains. This partnership enables CIQ to scale its operations beyond Bolivia’s borders, leveraging established trade agreements and documented regulatory pathways to access new international markets.
Dr. Bascope, a renowned scientist and visionary in the field, sees this partnership as an evolution in sustainable pharmaceutical production. “This joint venture expands CIQ’s potential far beyond Bolivia, allowing us to introduce our botanical extracts and APIs to new markets while advancing scientific research through KRTL Biotech’s regulatory expertise,” said Dr. Bascope.
Infrastructure & Sustainable Development
The joint venture will also facilitate the development of three key facilities, two in Quillacollo and Santa Cruz, and a third in Cochabamba in partnership with SIGMA, enhancing Bolivia’s growing role in global biotech manufacturing. KRTL International will oversee infrastructure expansion, including carbon credit initiatives and reforestation projects, while KRTL Biotech manages regulatory compliance, enabling products to meet stringent U.S. and international pharmaceutical standards.
Innovation at the Core: The Future of API Production
Beyond land acquisition, this collaboration secures KRTL Biotech’s access to CIQ’s extensive library of exotic molecules, which are subject to further regulatory review and approval under FDA guidelines before pharmaceutical application, opening doors to pharmaceutical advancements in pain management, anti-inflammatory treatments, and dermatological applications. Moreover, with partnerships spanning over 40 international universities, CIQ provides a foundation for cutting-edge research and innovation in molecular biology and sustainable chemistry, creating further opportunity in the US considering today’s geopolitical landscape.
A Commitment to Sustainable Pharmaceutical Leadership
As global biotech markets seek alternatives to traditional supply chains, KRTL Holding’s expansion into Bolivia presents a forward-thinking approach that benefits both economic and environmental sustainability. With Sigma Corp. as a key manufacturing partner, the venture ensures efficient production and distribution, reinforcing Bolivia’s role as a rising force in pharmaceutical innovation.
Cesar Herrera, CEO of KRTL Holding Group, Inc., emphasizes the significance of this milestone: “KRTL continues to expand strategically, forming key international collaborations to strengthen market access, supply chain control, operational capabilities and enhancing our partnerships, which combined with our FDA registrations, gives us the ability to sell pharmaceutical products from Bolivia in the US.”
Final Thoughts: A Game-Changer in the Making
With this strategic move, KRTL Biotech is not just expanding its footprint—it is redefining the future of pharmaceutical production. By embracing Bolivia’s biodiversity, investing in research, and ensuring compliance with international regulations, KRTL Biotech is paving the way for a sustainable and innovative biotech ecosystem.
As KRTL Holding continues its strategic growth, each press release represents a piece of a larger, evolving journey. These updates highlight key milestones and initiatives, but the full scope of KRTL's vision will become increasingly clear with future announcements. We encourage stakeholders to follow our progress as we integrate innovation, sustainability, and market expansion into a comprehensive strategy for long-term success.
About KRTL Biotech Inc.: KRTL Biotech Inc., a wholly owned subsidiary of KRTL Holding Group Inc., specializes in pharmaceutical registration, regulatory compliance, and FDA services for both international and domestic clients. The company plays a pivotal role in product registration and importation, ensuring seamless integration into the U.S. market. In addition, KRTL Biotech excels in client acquisition, sourcing exclusive APIs, and providing strategic regulatory guidance. Their innovative approach to navigating the complexities of pharmaceutical compliance and market entry positions them as a key driver of success for their partners and clients.
About Centro de Investigaciones Químicas, S.R.L: CIQ S.R.L. is a premier Bolivian research and manufacturing institution specializing in the extraction, refinement, and application of high-value natural compounds. Under the leadership of Dr. Bascope, CIQ collaborates with a global consortium of research institutions, advancing the frontiers of cosmetic science, pharmaceutical innovation, and industrial biochemistry. With a focus on sustainable resource utilization and pioneering research methodologies, CIQ remains a leader in advancing Bolivia’s scientific innovation and commercial applications for bioactive compounds.
About KRTL Holding Group Inc.: KRTL Holding Group Inc. operates through its wholly owned subsidiaries, KRTL Biotech Inc. and KRTL International Corp., focusing on pharmaceutical innovation and compliance. By fostering strategic partnerships and leveraging synergies across its subsidiaries, KRTL Holding Group enhances shareholder value and maintains a competitive edge in the marketplace.
The information contained herein includes forward-looking statements, as defined under the Private Securities Litigation Reform Act of 1995. These statements relate to future events or financial performance and involve risks and uncertainties, including but not limited to market conditions, regulatory approvals, operational challenges, and other factors that could cause actual results to differ materially from those anticipated. KRTL assumes no obligation to publicly update or revise these statements to reflect changes in circumstances or unforeseen events, except as required by law.
